Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
复制标题
DOI：
10.1111/dth.13118
复制
发表时间：
2019-10-21
影响因子：
3.6
通讯作者：
Atakan, Nilgun
中科院分区：
文献类型：
--
作者：
Akdogan, Neslihan;Ersoy-Evans, Sibel;Atakan, Nilgun
斑秃(AA)是一种导致无疤痕脱发的常见疾病。近年来，托法替尼(tofacitinib，TOFA)已成为治疗再生障碍性贫血的一种有前景的新疗法。本研究的目的是确定口服TOFA治疗斑秃(AA)和全面性秃发(AU)的疗效。对9例接受口服TOFA治疗的AA或AU患者的资料进行了回顾性评估。治疗结果、疾病严重程度和治疗反应通过脱发严重程度工具(SALT)评分以及在第三个月和第六个月进行定期照相监测来评估。所有患者的治疗反应分为4类：完全缓解(最新SALT评分变化90%)、中度反应(51%~90%变化)、中度反应(6%~50%变化)、无反应(SALT评分变化5%~100%)41.4%。对TOFA有反应的患者大多为AA而不是AU。不良反应轻微。TOFA的临床有效率似乎是合理的，在这个队列中TOFA的耐受性很好。然而，为了真正评估疗效，未来的研究还需要在随机对照试验中评估TOFA治疗的有效性、不良反应和持久性。
Alopecia areata (AA) is a common disease that results in nonscarring hair loss. Recently, tofacitinib (TOFA) has been a novel promising therapy for AA. The aim of this study is to determine the efficacy of oral TOFA treatment for alopecia areata (AA), and alopecia universalis (AU). Data of nine patients treated with oral TOFA with either AA or AU were retrospectively evaluated. Treatment outcome, disease severity, and therapeutic response were evaluated by Severity of Alopecia Tool (SALT) scores along with regular photographic surveillance done at third and sixth months. Treatment response was established on four categories: complete response (90% change in latest SALT score), intermediate response (51-90% change), moderate response (6-50% change), and nonresponse (= 5-100% change in SALT score) was 41.4% for all patients. Most of the patients who responded to TOFA had AA instead of AU. Adverse effects were mild. The clinical response rate of TOFA seems reasonable and TOFA was well-tolerated in this cohort. However, to truly evaluate efficacy, future studies are needed to assess the efficacy, adverse effects, and durability of treatment with TOFA in randomized controlled trials.